In our study, we showed that the ERBB2 amplification was found mostly in 6% of HGSC, which is consistent with the study of Kohei Nakamura et al. showing that ERBB2 and KRAS amplification were detected in HGSC as actionable cancer-related genetic alterations29.We were not able to show a higher amplification rate in mucinous tumors as we included only 4 mucinous carcinomas in our cohort30. This evidence concerns the gene KRAS and mucinous adenocarcinoma.